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Abstract 
 
Unilateral vocal fold paralysis (UVFP) results from an injury to the recurrent or the vagal nerve. 
The main symptom of UVFP is a breathy, weak voice.  Surgery is warranted for patients in whom 
spontaneous reinnervation and a course of voice therapy fails to improve the voice. Three surgical 
methods are available.  Laryngeal framework surgery and injection laryngoplasty offer static 
approaches, which aim to improve glottal closure by repositioning the paralyzed vocal fold 
permanently to the adducted position. Reinnervation procedures succeed to restore vocal fold 
muscle tone without dynamic movement, but being technically demanding, they have not been 
universally accepted.  Laryngeal framework surgery is regarded as the gold standard, but injection 
laryngoplasty is also widespread. The technique of injection was introduced a century ago, but the 
search for an ideal injection material is ongoing. Currently, there exists a great diversity of 
synthetic, xenologous, homologous, and autologous substances available for vocal fold 
augmentation by injection. An autologous graft is perfect in terms of biocompatibility. High 
reabsorption rate and subsequent transient treatment outcome have imposed a major problem with 
fat, the first widely used injectable autologous graft.   
 
Free fascia grafts have been successfully used in the head and neck surgery for decades. The 
purpose of this work was to study the applicability of minced autologous fascia graft for the 
injection laryngoplasty of UVFP by experimental animal study and series of clinical trials.  
Permanence of augmentation and host versus graft tissue reactions were of special interest.   
 
In the animal study of 9 canines, histological analysis of the graft and surrounding vocal fold tissue 
revealed mild to moderate inflammation initially. No chronic inflammatory response was present at 
6 and 12 months. No extensive oedema, areas of necrosis, or granuloma formation was found at any 
time. At 12 months the graft had integrated into the vocal fold tissue forming a firm tissue mass 
with viable fibrocytes, remodelled collagen bundles with parallel orientation, and blood supply with 
arterioles and venules. Scarring was mild around the graft. A foreign-body reaction was found 
around small polyamide particles, which originated from the polymer plate on which the graft was 
minced with a scalpel. The finding of polyamide crystals in the graft at 12 months was important. It 
was an affirmation to the pathologist, that the collagen-rich bundle found in the vocal fold of the 
dogs was man-made. It also led to a modification of the surgical technique; we began to mince the 
fascia with scissors on a glass plate after this finding. 
 
Three series of clinical trials of injection laryngoplasty with autologous fascia (ILAF) during a 
period of ten years were conducted to document the possible morbidity related to graft harvesting 
and vocal fold injection. Improvement of voice quality was measured by multiple objective 
parameters of voice evaluation. Surgery was performed only on patients in whom several sessions 
of voice therapy had failed to improve the voice sufficiently.  The preliminary results were studied 
in a prospective trial of 18 patients.  Mean follow-up was 9 months (range 4-25).  The maximal 
phonation time (MPT) and parameters of acoustic analysis indicated better voice quality after 
intervention. The second trial with 14 patients documented the intermediate term results with a 
mean follow-up of 13 months (range 5-32). Voice quality measured by perceptual evaluation and 
acoustic analysis was improved significantly and the integrity of vocal fold closure was enhanced as 
measured by MPT.  Improved glottal closure and return of mucosal wave phase symmetry were also 
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evident in videostroboscopy.  No immediate complications related to graft harvesting or injection 
procedure occurred. The postoperative inflammatory reaction in the vocal fold was mild without a 
need for antibiotics or corticosteroids. At the donor site, two prolapses of the vastus lateralis muscle 
occurred later, one of which was surgically corrected.  No complaints were made of an aesthetically 
disturbing scar on the thigh. No over-correction of the vocal fold was seen postoperatively; the graft 
had been molded to appropriate size by the dynamic forces exerted on the vocal fold.  The 
retrospective third trial consisted of 43 patients with a median follow-up of 5.8 years (range 3-10). 
Voice quality was rated improved in perceptual evaluation. In acoustic analysis, statistically 
significant improvement was measured in jitter. Postoperative videostroboscopy demonstrated 
complete or partial glottal closure in 83% of patients and mucosal wave phase symmetry in every 
cycle or most cycles in 74% and amplitude symmetry in 58%. The mean voice handicap index 
(VHI) postoperatively was 35 (median 29). The VHI was below 30 (normal or near normal voice) 
in 56%. Length of follow-up or delay from onset of paralysis to injection had no significant effect 
on the results. Neither was the age of the patient relevant. Poor preoperative voice measured by 
perceptual evaluation and paralysis caused by an intrathoracic lesion correlated with poor outcome. 
 
Our results indicate that autologous fascia is a feasible injection material for UVFP patients. 
Harvesting of the graft on the lateral thigh and injection into the vocal fold is met with minor 
morbidity. Fascia is well tolerated by the vocal fold.  When injected deep and laterally into the TA 
muscle, the fascia graft allows normal vibration of the vocal fold mucosa. Voice quality is 
significantly improved provided that sufficient augmentation and glottal closure is achieved.  
Although some resorption or compaction of the graft during the first months is evident, graft 
volume is maintained well. This stability is reflected by the satisfactory voice results after long 
follow-up. 
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Abbreviations 
 
ANOVA  analysis of variance 
CNS  central nervous system 
CT  computerized tomography 
ECM  extracellular matrix 
EMG  electromyography 
ENT  Ear, Nose and Throat- speciality of medicine 
FDA  Food and Drug Administration of USA 
GRBAS  scale for perceptual evaluation of voice 
HA  hyaluronic acid 
IA  interarytenoid muscle 
IL  injection laryngoplasty 
ILAF  injection laryngoplasty with autologous fascia 
LCA  lateral cricoarytenoid muscle 
MPT  maximal phonation time 
MRI  magnetic resonance imaging 
NHR  noise-to-harmonics ratio 
PCA  posterior cricoarytenoid muscle 
RLN  recurrent laryngeal nerve 
SLN  superior laryngeal nerve 
TA  thyroarytenoid muscle 
UVFP  unilateral vocal fold paralysis 
VAS  visual analogue scale 
VHI   voice handicap index 
VN  vagal nerve 
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1 Introduction 
 
The main complaint of patients with unilateral vocal fold paralysis (UVFP) is a breathy, weak or 
even aphonic voice. Failure to close the glottis may also lead to dysphagia; inability to cough and 
shout; dyspnoea and fatigue related to lifting and straining. The disability and handicap in work 
performance and other daily tasks is rated by patients equivalent to conditions such as coronary 
heart disease, sciatica, and chronic sinusitis (Benninger, Ahuja et al. 1998). 
 
UVFP is a relatively common finding in tertiary otolaryngological practice, although its exact 
incidence has not been established (Benninger, Crumley et al. 1994; Rubin and Sataloff 2007). The 
most common causes of UVFP are neoplasms (brain stem, neck, chest, mediastinum), surgical 
trauma (thyroid, neck, chest) and neurological disorders. UVFP may result from an injury to the 
vagal nerve (VN) or its laryngeal branch, the recurrent laryngeal nerve (RLN).  Unilateral injury to 
the RLN is the most common and leads to paralysis or paresis of all intrinsic laryngeal muscles 
except the cricothyroid, which is innervated by the superior laryngeal nerve (SLN).  In a high VN 
lesion, the functions of both laryngeal nerves are impaired resulting in aggravated symptoms.  
Paralysis of the RLN is characterized by ipsilateral flaccidity of the vocal fold and loss of 
movement (abduction and adduction). The vocal fold remains in different stages of abduction 
depending on the extent of injury and subsequent reinnervation (Crumley 1994).  Prognosis varies 
greatly according to the etiology. In idiopathic paralysis, generally a period of one year is waited 
before irreversible treatment decisions are made (Sulica 2008). 
 
The primary goal of treatment in UVFP is to eliminate aspiration and to improve voice. A course of 
voice therapy is commonly considered beneficial to the patient to prevent compensatory 
hyperfunctional phonatory behaviour (Benninger, Crumley et al. 1994). After failure of spontaneous 
recovery, accommodation or appropriate voice therapy, surgery may be considered. The percentage 
of UVFP patients requiring surgery is rarely reported. One article reported of a group of 160 
patients with RLN paralysis of whom 20% were treated by surgery (Heuer, Sataloff et al. 1997).  
Surgical treatment modalities currently available for UVFP include injection laryngoplasty (Arnold 
1962), laryngeal framework surgery (Isshiki, Morita et al. 1974) and laryngeal reinnervation 
(Tucker 1977; Crumley 1991). Experience of the surgeon and patient-related factors determine the 
method of choice to achieve optimal results.  Laryngeal framework surgery is currently the gold 
standard against which other methods of surgical intervention are judged (Benninger, Crumley et al. 
1994; Kwon and Buckmire 2004).  However, injection laryngoplasty has several appealing qualities 
including relative technical ease, low cost and wide availability in many clinical settings, which 
have contributed to its widespread use in the general otolaryngological community (Kwon and 
Buckmire 2004). 
 
The goal of injection laryngoplasty in UVFP is to medialize the paralyzed vocal fold by augmenting 
its mass, which enables the mobile, unaffected fold to close the glottis. The surgical technique was 
established long ago (Bruning 1911), but search for a suitable injebtable substance is ongoing. 
Teflon® injection (paste of polytetrafluoro-ethylene) was the mainstay of surgical treatment of 
patients with glottal insufficiency for decades (Dedo, Urrea et al. 1973). Due to many long-term 
side-effects (foreign-body reaction, migration of particles) related to Teflon®, it has been excluded 
from the practice of modern laryngology (Kwon and Buckmire 2004).   
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The ideal soft-tissue filler substance should be safe, biocompatible, nonmigratory, resistant to 
phagosytosis, pliable, and should persist and maintain its volume without being absorbed. Although 
a growing number of injectable substances have been developed and tested, no single substance has 
yet been able to fully meet all these criteria (Broder and Cohen 2006). The substances are 
categorized by the origin of material as synthetic material, xenograft, homograft (allograft) and 
autograft (Kwon and Buckmire 2004; Eppley and Dadvand 2006).   
 
After the adverse foreign-body reactions related to Teflon® became apparent, research was directed 
to find a more biocompatible material.  Autologous fat seemed to be attractive from many aspects. 
Initial clinical trials with humans reported good short-term outcome of autologous fat injection 
laryngoplasty (Mikaelian, Lowry et al. 1991; Brandenburg, Kirkham et al. 1992).  However, a later 
study has shown an unpredictable rate of absorption of fat after three months (Shindo, Zaretsky et 
al. 1996). In many cases, repeat injections are necessary to maintain adequate vocal fold bulk 
(Kwon and Buckmire 2004). The unpredictable long-term outcome has advocated opinions that fat 
injection is not a preferable method of surgery in UVFP (McCulloch, Andrews et al. 2002; 
Laccourreye, Papon et al. 2003). Some authors still see the potential in the fat graft, once specific 
technical details are taken into consideration (Sataloff 2005). 
 
Another autologous graft, free fascia, was proposed for injection laryngoplasty to address the poor 
persistence of fat in the larynx (Rihkanen 1998).  Autologous free fascia transplantation has been 
used in plastic, reconstructive, and head and neck surgery for a century (Boyce, Nuss et al. 1994). 
Fascia has been proven to be a stable and predictable graft material for various head and neck 
indications and suitable for augmentation of small-volume soft-tissue defects (Miller 1988). 
Theoretically, fascia was thought to be more stable than fat in the larynx, while having the 
advantages of autologous grafts being safe, of low cost, readily available, biocompatible, and 
pliable.  
 
After the initiation of this work in 1998, several new biomaterials have been introduced for 
injection laryngoplasty in humans including homologous collagen, Cymetra (Pearl, Woo et al. 
2002), autologous collagen (Ford, Staskowski et al. 1995),  and xenologous hyaluronic acid 
(Hertegard, Hallen et al. 2004). All have been reported to offer satisfactory vocal results in short-
term studies, but long-term studies are lacking.  
 
The aim of this work was to study the suitability of minced autologous fascia in the treatment of 
UVFP with injection laryngoplasty. The injectable substances available by 1998 had problems 
related either to poor biocompatibility (Teflon®, silicone) or unpredictable persistence in the larynx 
(fat, bovine collagen). Autologous fascia grafts had previously been well-tolerated and stable in the 
head and neck surgery, but had not been grafted in processed form into a host tissue exposed to 
mechanical strain. 
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2 Review of the literature 
 
 
2.1. Transplantation of autologous fascia 
 
2.1.1. Fascia grafts in the head and neck surgery 
 
Otolaryngologic, plastic and reconstructive surgery of the head and neck region embraces a number 
of situations that may call for reconstruction or augmentation using a soft-tissue substitute.  The 
perfect autologous graft should have the following characteristics: easily accessible and available in 
large quantities; little donor site morbidity; nonmutagenic; sustain a low infection rate; easily 
tailored and sculptured; and finally, sustain a low or at least predictable resorption rate (Boyce, 
Nuss et al. 1994). 
 
Unfortunately, no single material universally satisfies these requirements, although fascia has some 
unique advantages. Results of fascia grafting are quite predictable and often gratifying (Boyce, 
Nuss et al. 1994). Therefore, fascia transplantation has been used over a century for a variety of 
indications in the head and neck surgery. Common clinical examples, which take advantage of 
fascia´s tensile strenght include tympanoplasty, correction of facial paralysis, replacement of dura 
after trauma or tumor surgery, and correction of ptosis.  Fascia has also been employed as “filler” to 
augment small-volume soft-tissue defects in aesthetic applications such as the nasal dorsum, the 
nasal tip, the nasolabial angle, the thin lip and the underprojected chin. 
 
Autologous fascia can be harvested from multiple donor sites: fascia lata in the lateral thigh; 
aponeurosis of the anterior abdominal wall, rectus abdominis sheath and the temporal region 
(superficial and deep temporal fascia).  Fascia lata is perhaps the best site for augmentation 
purposes, because here the fascia is thick and can be harvested in large amounts without 
considerable donor site morbidity (Boyce, Nuss et al. 1994). Major disadvantage is a scar on the 
thigh, which can be sometimes aesthetically objectionable. In the head and neck surgery, the need 
for operating on a remote surgical site may also be considered time-consuming and adding to 
morbidity. Therefore, temporal fascia is favoured by some surgeons (Miller 1988). 
 
In terms of recipient site characteristics (sterility, hemostasis, mobility of the recipient area, quality 
of the recipient bed) transplanted fascia seems to have modest demands. As a free tissue transplant, 
fascia requires some vascularity from the recipient bed in order to survive.  However, this need 
seems to be less pronounced for fascia than for other graft types. Complications of fascia 
transplantation are uncommon.  Single-layer fascia grafts are remarkably tolerant of local 
inflammation (Guerrerosantos 1991) and can be applied to contaminated and infected tissues.  For 
example, fascia is used as a tympanic membrane graft after mastoidectomy for chronic ear 
infection. The risk of infection probably increases with growing thickness of the graft because of  
reduced vascularity to the central portion of the transplant (Boyce, Nuss et al. 1994). The main 
limitation of free fascia transplantation is the lack of three-dimensional bulk restricting its use to 
relatively small-volume defects. 
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2.1.2. Histology of the transplanted autologous fascia 
 
Recipient site characteristics play a major role in the survival of tissue transplants. An animal model 
is often applied to study the tissue reactions between the host and the graft. Histological evaluation 
of harvested grafts usually includes assessment of the degree of inflammation, preservation of tissue 
structure, the presence of nuclei within the cells of the transplanted tissue and the degree of 
neovascularization. Examination of normal fascia shows a single cell type, the fibroblast, and an 
intercellular matrix composed of collagen. It is probably because of this simple basic structure, 
combined with low metabolic rate, that fascia can be transplanted without major alterations in its 
form and function (Peer 1959). 
  
A controlled animal study compared how the form of the graft and the vascularity of the recipient 
site affect the fate of the fascia transplant.  Single-layer and four-layer autologous grafts of 
thoracodorsal fascia were transplanted either on the cranial bone (nonvascularized) or the cranial 
periosteum (vascularized) of rabbits. From the histological examination it was evident that multi-
layered fascia grafts or single-layer grafts placed directly on bone do not survive as viable tissue. 
The collagen structure appeared to be maintained without preservation of viable fibroblasts and any 
ingrowth of a new vascular supply. In contrast, in the single layer graft placed on the vascular 
periosteum, the tissue viability was maintained.  The multi-layered graft maintained its bulk, and 
together with the lack of inflammatory infiltrate this indicates that the breakdown or turnover of 
collagen within this avascular matrix was extremely slow. This was interpreted to support the use of 
multi-layered grafts when only bulk is desired. In other words, the fascia graft survival was not 
dependent on the viability of its cellular elements (Das, Davidson et al. 1990).   
 
In humans, temporal muscle fascia applied to augmentation of the nasal dorsum has been reported 
to undergo approximately a 20 % shrinkage of bulk in the first 4 to 6 weeks postoperatively based 
on a visual estimate and remain stable thereafter.  It was deduced from the histological sections that 
the shrinkage was the result of compaction and condensation of the graft rather than resorption.  No 
inflammation or encapsulation was seen clinically or histologically (Miller 1988).  
 
The physical forces to which the graft is exposed to may challenge its survival in various ways. 
When used for tensile applications as a single-layer graft it is essential that a strong healing can 
occur between the fascia transplant and its bed in order for it to withstand the anticipated strain 
(Gallie 1948).  A study with dogs demonstrated how grafted autologous fascia heart valves 
deteriorated in 8 weeks when exposed to the blood stream. Fascia lost the adhering layer of 
fibroblasts and surface compounds. The collagen scaffold of the graft was laid bare and liable to 
further breakdown by endothelialization and collagenase secretion of the invading cells (Bharadwaj, 
Kurylo et al. 1975).  
 
 
2.1.3. Fascia grafts in the larynx 
 
The vocal fold forms a unique physiological environment for any tissue transplant. It is a dynamic 
structure even when paralyzed.  Changes in subglottal air pressure on coughing and phonation, and 
movement of the larynx during swallowing predisposes the graft to mechanical strain.  Mobility of 
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the recipient area has been reported to affect the outcome with fat transplants by disturbing the 
formation of vascular anastomoses (Peer 1959). Studies with transplanted fascia have been 
conducted by placing the graft into relatively static areas of the body.  Before our series of ILAF, 
extreme processing of the fascia graft before transplantation had not been studied. Most 
experiments had been conducted with fascia grafted in a single-layer or, at the most, rolled, bunched 
or layered.  Mincing the fascia before injection disrupts its infrastructure, and theoretically, could 
have exposed collagen and other components of connective tissue to proteolytic activity. This might 
have had a negative effect on the outcome of ILAF. 
 
Another phonosurgical technique taking advantage of autologous fascia has been developed to treat 
vocal fold sulcus and scarring (Tsunoda, Takanosawa et al. 1999). The graft is harvested from the 
temporal fascia. Under suspension microlaryngoscopy, an incision is made on the lateral aspect of 
the vocal fold and a pocket is undermined under the sulcus or scarred vocal fold mucosa. A single-
layer fascia graft is dried and trimmed, and transplanted into the pocket. After extrusion of the graft 
during coughing, the authors recommended suturing the incision. Complete voice rest for two 
weeks after the procedure is recommended.  Outcome measurements showed excellent results in 
nine patients with a follow-up between 1-3 years (Tsunoda, Baer et al. 2001).  Temporal fascia 
appeared to be suitable for transplantation into the Reincke´s space with a low risk of infection. The 
authors even speculate that transplantation leads to regeneration of vocal fold tissue by a 
mechanism similar to stem cell transplantation, since the results in MPT and stroboscopy continued 
to improve beyond one year. Long-term results of ten patients treated for sulcus vocalis with a 
follow-up of at least 3 years has been reported. The improvement in MPT was significant (p < .01) 
at three years and “satisfactory glottal closure and excellent mucosal wave were observed for all 
cases” in stroboscopy at one year. The authors performed immunohistologic staining of an extruded 
fascia specimen with the anti Ki-67 antibody.  High proliferative activity in the fibroblasts of 
transplanted fascia was recognized. This may indicate that autologous fascia graft in the superficial 
lamina propria of the vocal fold can induce production and proliferation of extracellular matrix 
(Tsunoda, Kondou et al. 2005).  
 
 
2.2. Unilateral vocal fold paralysis 
 
2.2.1. Definitions and terminology 
 
Vocal fold paralysis implies vocal fold immobility due to neurologic injury. Vocal fold paresis 
implies vocal fold hypomobility due to neurologic injury (Rubin and Sataloff 2007). Signs and 
symptoms of vocal fold paralysis depend on which nerve has been injured; the RLN or both RLN 
and SLN. The therapeutic strategies are different in unilateral or bilateral nerve injury.  In this work 
the focus is on UVFP caused by an injury of the RLN or of both RLN and SLN.   
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2.2.2. Laryngeal anatomy and biomechanics 
 
The larynx has complex functional demands in respiration, phonation, stabilization of body core 
during physical activity, and airway protection during swallowing. A thorough understanding of 
vocal fold anatomy (histologic and gross) and physiology is required to optimize treatment outcome 
for patients with vocal complaints.  Adequate respiratory support, appropriate glottal closure, 
normal vocal fold cover, and control of vocal fold length and tension are required for normal 
phonation (Noordzij and Ossoff 2006). 
 
The larynx is innervated by the RLN and the SLN, which both are branches of the tenth cranial 
nerve, the VN.  The motor branches of the VN originate from the nucleus ambiguus in the medulla 
of the brain stem. The VN exits the skull through the jugular foramen together with the 
glossopharyngeal (IX) and accessory (XI) cranial nerves. The SLN is divided from the VN just 
below the inferior (nodose) ganglion. The external motor branch of the SLN descends below the 
thyroid cartilage into the cricothyroid muscle. The sensory internal branch pierces the thyrohyoid 
membrane along with the superior laryngeal artery and supplies the sensation of the supraglottal 
larynx.  The RLN axons travel with the VN down the neck until they branch off at the level of the 
subclavian artery on the on the right, and the aortic arch on the left. Both RLNs travel upwards 
(cranially) lateral to the tracheoesofageal groove and enter the larynx behind the cricothyroid joint.  
The RLN is the principal motor nerve of the intrinsic muscles of the larynx and responsible for 
sensation of trachea below the glottis and upper esofagus (Rubin and Sataloff 2007).  
Embryology explains the difference in the course of the recurrent nerves. In the embryo, the left 
RLN curves around the ductus arteriosus, which is eventually located caudal to the arch of the aorta. 
On the right, the proximal part of the sixth aortic arch forms the right pulmonary artery, and the 
distal part of the sixth aortic arch loses its connection with the embryonic dorsal aorta, and 
disappears. The right RLN is then able to curve around the more cranial artery of the fourth aortic 
arch, the subclavian artery (Langman 1969). It is noteworthy, that 5 out of 1000 people have a 
nonrecurrent laryngeal nerve on the right (Rubin and Sataloff 2007). 
 
The RLN contains from 500 to 1000 motor axons, most of which pass to the adductor muscles of 
phonation; the thyroarytenoid (TA), the interarytenoid (IA) and the lateral cricoarytenoid (LCA). 
About one fourth of the fibers are destined to the sole abductor muscle, the posterior cricoarytenoid 
(PCA), which opens the glottis for inspiration.  The innervation of the intrinsic laryngeal muscles is 
unilateral except for the IA, which receives contributions from both RLNs. Each RLN is also 
thought to contain fusimotor efferent axons as well as vasomotor and secretomotor fibers of 
symphatetic and parasymphatetic origin (Crumley 1989). To a lesser degree, extrinsic laryngeal 
muscles also affect vocal fold shape and movement.  The strap muscles, innervated by the ansa 
hypoglossi act as accessory muscles of forced inspiration (especially the sternothyroid muscle) 
while the thyrohyoid muscle is accessory to phonation and other adductive functions (Crumley 
1985).  
 
The cover-body theory and aerodynamics explain the vocal fold vibration. Vocal fold body, formed 
primarily by the TA muscle, is responsible for most of the transverse motion of the vocal fold. The 
looser mucosal cover forms the travelling mucosal wave (Hirano and Kakita 1985).  
Aerodynamically, the conical shape of the larynx and adducted vocal folds increase air stream 
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velocity at the rima glottidis during phonation. Increased velocity in turn creates a negative air 
pressure on the medial edge of the vocal fold according to the law of Bernoulli. This suction effect 
combined with the myoelastic properties of the vocal fold and the constant air stream is the driving 
force of vibration. The mucosal wave is present only if there is a pliable mucous membrane 
covering the vocal fold, but active neuronal activity of the muscle is not a prerequisite of vocal fold 
vibration per se (Kokesh, Flint et al. 1993).  Histologically, the vocal fold consists of five layers: the 
squamous epithelium, the superficial-, intermediate- and deep layer of lamina propria, and the TA 
muscle. The extracellular matrix of the lamina propria is mainly responsible for the elasticity of the 
vocal fold cover and its optimal vibratory characteristics (Noordzij and Ossoff 2006). Any surgical 
intervention to enhance voice production must retain this elasticity and avoid damage to the 
undulating cover. 
 
2.2.3. Incidence, etiology and prognosis 
 
The incidence of UVFP has not been established, although it is fairly often encountered by 
otolaryngologists (Benninger, Crumley et al. 1994; Rubin and Sataloff 2007). The most common 
causes of RLN injury are tumour infiltration or compression 40 % (brain stem, neck, chest, 
mediastinum), surgical trauma 35 % (thyroid, anterior cervical spine, chest), trauma (mostly 
intubation) 8%, and idiopathic 11 % (Terris, Arnstein et al. 1992).  Others include cerebrovascular 
accidents, CNS tumours, bulbar lesions, neurodegenerative disease, infectious causes and several 
systemic diseases (Rubin and Sataloff 2007). When the cause of paralysis remains unclear, it is 
termed idiopathic; some suspect infection (Lyme disease, Epstein-Barr and herpes virus). Idiopathic 
causes are probably more common than reported because they may resolve spontaneously before 
patients seek medical attention (Benninger, Crumley et al. 1994).  
The natural history of vocal fold paralysis depends on the mechanism and degree of injury to the 
nerve. The clinical course is determined by the degree of reinnervation and synkinesis.  The 
Sunderland classification system describes five different degrees of neural injury (Sunderland 
1978).  Neurapraxia (1. degree) and axonotmesis (2nd degree) injuries should recover completely. 
Third-degree injury includes endoneural scarring, which can cause misdirected regeneration known 
as synkinesis. Synkinesis results from nonselective innervation of adductor and abductor muscles. 
As a result, muscles that perform opposite functions contract simultaneously, resulting in 
immobility or hypomobility of the vocal fold. A classification system for laryngeal synkinesis has 
been described (Crumley 2000). Fourth-degree injury involves scarring that blocks regenerating 
axons and fifth-degree injury signifies complete transection of the nerve.  
 
With idiopathic paralysis the prognosis is difficult because of marked variation in degrees of neural 
injury and rates of spontaneous recovery. Generally, a period of one year is waited before 
irreversible surgical treatment decisions are made (Rubin and Sataloff 2007; Sulica 2008). 
 
2.2.4. Symptoms and laryngologic findings 
 
The main complaint of patients with UVFP is a breathy, weak or even aphonic voice. The open 
glottal gap constitutes the greatest physical factor that compromises voice quality.  Failure to close 
the glottis may also lead to dysphagia with aspiration; inability to cough and shout; dyspnoea and 
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fatigue related to lifting and straining.  Patients who have vocal fold paralysis deserve 
comprehensive evaluation, which begins with a thorough history and meticulous physical 
examination followed by adequate CT or MRI imaging to define the cause of the paralysis (Terris, 
Arnstein et al. 1992; Rubin and Sataloff 2007).  
 
Videostrobolaryngoscopy provides invaluable visual information of the vocal fold motion and 
vibratory characteristics of the vocal fold mucosa in slow motion allowing meticulous analysis and 
a permanent document. The vocal fold movement and vibration is evaluated during various 
phonatory tasks at several frequencies and intensities. The laryngologist should look for asymmetric 
movement, vocal fold bowing, horizontal and vertical position of the vocal folds, and tilting of the 
posterior larynx (Rubin and Sataloff 2007). Depending on the site and extent of injury, degree of 
reinnervation, synkinesis, and compensation, findings vary among individual patients (Benninger, 
Crumley et al. 1994). In unilateral RLN injury, the vocal fold remains in different stages of lateral 
position (mostly a paramedian position) and only slight, if any, movement of the fold is detectable 
during phonation. Due to the loss of tone and mass of the body (TA muscle), the vocal fold is 
flaccid with concave bowing. The difference in length and tone of the vocal folds leads to 
asymmetry that alters the vibratory characteristics, and is seen under stroboscopic light as 
aperiodicity of frequency and asymmetric amplitude of the mucosal wave. A high vagal lesion 
combines the effects of SLN and RLN paralysis with enhanced flaccidity and bowing, and a wide 
glottal gap. A shift of the posterior glottis to the side of the SLN injury may be seen.  Vagal 
paralysis also leads to a difference in the vertical position of the vocal processes of the arytenoid 
cartilages. Therefore, surgical procedures that address this vertical disparity are more effective in 
improving glottic closure and vocal quality (Isshiki, Tanabe et al. 1978; Benninger, Crumley et al. 
1994). 
 
Vocal fold position alone does not allow determining the site of the neurological lesion. In many 
cases, laryngeal EMG is considered helpful in confirming the clinical impressions. It is of special 
value in cases of arytenoid fixation, dislocation or subluxation, which are frequently mistaken for 
vocal fold paralysis (Woo 1998; Rubin and Sataloff 2007). 
 
 
2.3. Role of voice therapy in treatment of UVFP 
 
Minimal outcome and efficacy data on voice therapy for UVFP are available (Behrman 2004; 
Miller 2004). Only two nonrandomized retrospective studies comparing the efficacy of voice 
therapy with surgical treatment have been published (Heuer, Sataloff et al. 1997; Kelchner, Stemple 
et al. 1999). Heuer et al. studied 41 patients with UVFP of whom more than half elected to have 
voice therapy instead of surgery. Outcome measure data showed similar satisfaction in the therapy 
and surgery groups, though post treatment objective measures were not obtained.  Kelchner et al. 
conducted a review of 25 patients. Post treatment stroboscopic examination and perceptual 
assessment of voice revealed comparable outcomes between surgery (N=13) and voice therapy 
(N=6).  Both studies have been criticized for selection bias, since patients who elected voice therapy 
had less severe laryngeal dysfunction based on the pre-treatment evaluation. In cases where voice 
therapy yields improved voice, it is unclear whether it is a result of increased phonatory closure or 
improved compensatory techniques (Behrman 2004).  
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Even though the effect of voice therapy in the management of UVFP remains unclear, it is 
considered invaluable for several reasons (Benninger, Crumley et al. 1994; Miller 2004). Teamwork 
between the ENT-surgeon and the speech therapist is emphasized.  A speech therapist can not only 
quantify and document vocal dysfunction preoperatively, but also explore useful compensatory 
vocal strategies for the patient. Educating the patient about laryngeal functions, his/her specific 
abnormality, environmental manipulation, and vocal hygiene, relieves the anxiety and exhaustion 
related to this disorder (Miller 2004).  In addition, undesirable hyperfunctional phonation may be 
identified and corrected. It is common compensatory behaviour, and considered responsible for 
most of the voice strain, neck discomfort, and fatigue that often accompany UVFP. Also an estimate 
of how much the patient´s voice can be improved without surgery can be attained. Generally, 
several therapy sessions are needed to optimize the vocal function by progressive development of 
optimal breathing, abdominal support and intrinsic laryngeal strength and agility. In cases with mild 
to moderate glottal insufficiency, voice therapy alone may result in sufficient improvement of voice 
quality, avoiding the need for surgery (Benninger, Crumley et al. 1994; Miller 2004).  
 
If surgery is eventually required, preoperative voice therapy helps the patient while surgical 
decision is pending, provides training for optimal postoperative phonation, and prepares the patient 
psychologically for surgery (Benninger, Crumley et al. 1994). Postoperatively, a few sessions of 
voice therapy beginning 1  to 2 months after successful surgery is advocated to help the patients 
adapt their manner of voice production to a new mechanical condition (Isshiki 1998).  
 
 
2.4. Surgical treatment of UVFP 
 
After failure of spontaneous recovery, compensation by accommodation, or appropriate voice 
therapy, surgical intervention may be considered. The timing and the method of surgery is based on 
the patients´ voice needs and desire for improvement to accomplish their vocational, occupational 
or social functions. The two main surgical options for UVFP are medialization and reinnervation. 
Medialization procedures include laryngeal framework surgery (thyroplasty type I and arytenoid 
adduction) and injection laryngoplasty (Rubin and Sataloff 2007). The percentage of patients 
requiring surgery for UVFP is rarely reported. In one series of 160 patients with RLN paralysis, 20 
% of patients opted for surgery after unsatisfactory voice therapy outcome (Heuer, Sataloff et al. 
1997). 
 
2.4.1. Injection laryngoplasty 
 
 Injection laryngoplasty (IL) has long been an integral part of the therapeutic armamentarium for 
managing vocal fold paralysis.  UVFP results in a glottal gap of variable width. Augmentation of 
the paralyzed fold by injection shifts it towards midline permanently and aims to improve glottal 
closure.  Most ENT-surgeons prefer to inject materials into the vocal fold under general anesthesia 
with a rigid suspension endoscope and a specially designed syringe holder under microscopic 
control. Under local anesthesia a transcutaneous route through the thyroid cartilage or the 
cricothyroid membrane, with telescopic or flexible fiberoptic laryngoscopic control is possible. 
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Also transoral injection with indirect mirror guidance is an option in the out-patient setting (Sataloff 
2005). 
 
The potential advantages of IL include wide availability in many clinical settings, relative technical 
ease, low procedural cost and low morbidity. Avoidance of an open surgical procedure, as well as 
the option to the out-patient clinical setting makes it an appealing treatment modality to a wide 
spectrum of otolaryngologists (Kwon and Buckmire 2004).  
 
IL was first introduced in 1911 using paraffin as injection material (Bruning 1911).  Difficulties 
encountered with this synthetic material in other parts of the body (foreign-body reactions, 
extrusion, migration, and inflammation) led to abandonment of the technique also in the larynx for 
decades (Dedo, Urrea et al. 1973).  Intracordal injection was revived in the 1950s by experiments 
with autogenous cartilage and bone dust (Arnold 1955). Since then several synthetic and biologic 
materials have been used for vocal fold augmentation and the search for an ideal injection substance 
still continues. 
 
Appropriate patient selection is crucial for a successful outcome.  The ideal patient presents with a 
complaint and is motivated to seek improvement. Patience may be required along the course of this 
treatment, since the major disadvantage of most injectable substances has been the resorption over 
time. This creates the necessity for either re-injection or calculated over-injection initially to 
account for the projected loss of augmentation volume. Consequently, the best voice result is 
temporarily delayed or, at worse, transient (Kwon and Buckmire 2004).   
 
Another major limitation for IL is a large posterior glottal gap. Although some medialization of the 
affected arytenoid is possible by IL, it is not as precise as an open surgical approach such as 
arytenoid adduction.  Medical comorbidities are generally not considered contraindications for IL. It 
is also suited for selected patients, such as vocal professionals in need of a temporary relief of 
symptoms, when a full functional recovery of paralysis is expected.  Endoscopic injection 
techniques are also preferred to open surgery in patients with previous irradiation of the larynx, and 
active, or obstructing nonoperative disease (lymphoma, extensive fibrosis). IL can also be applied to 
other forms of glottal insufficiency such as vocal fold bowing or scarring (Kwon and Buckmire 
2004). 
 
The ideal injection material should be biocompatible; easily injectable; readily available with 
minimal preparation for optimal time efficiency and have the potential for application in outpatient 
office setting; comply with the biomechanical properties to the vocal fold; have a low resorption 
rate; be resistant to migration and easily removable.  At the moment, there exists a great diversity of 
substances available for IL.  They are categorized by the origin of material as synthetic materials, 
xenografts, homografts and autografts (Kwon and Buckmire 2004).  
 
Synthetic materials 
Synthetic substances are easily injected, readily available and provide permanent augmentation. 
After experiments with several substances Teflon® emerged as the material of choice (Arnold 
1962) and it became the favoured injection substrate for decades (Dedo, Urrea et al. 1973). Its 
permanence, ease of preparation and injection made IL available to many otolaryngologists.  
However, several long-term side effects became apparent. Complications with Teflon® were 
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related to the operative technique, migration of particles and giant-cell foreign-body reaction with 
granuloma formation.(Rubin 1965b; Lewy 1983; Varvares, Montgomery et al. 1995).  Removal of 
Teflon® at revision surgery proved to be difficult (Netterville, Coleman et al. 1998). Due to these 
problems, Teflon® has been excluded from the practise of modern laryngology (Kwon and 
Buckmire 2004).  
 
Injectable silicone was first introduced in the early 1960s (Rubin 1965a). In a large series of 240 
patients good vocal results with only one granuloma formation were reported using transcutaneous 
silicone injection through the cricothyroid space under local anaesthesia and monitoring the amount 
of augmentation by means of transnasal laryngeal fiberoscope (Hirano, Mori et al. 1995).  However, 
findings of substantial foreign-body giant cell reactions have led the FDA to declare the use of 
silicone for IL illegal in the United States (Kwon and Buckmire 2004). Regardless of this, silicone 
is still widely used in many other countries. 
   
During this decade, several new synthetic injectable materials have undergone trials in an effort to 
develop implants with improved biocompatibility and longevity.  Injectable calcium 
hydroxylapatite (CaHA) particles have been studied in a canine model. CaHA was well-tolerated, 
no migration to the lymphatic system and no resorption of particles was noted (Chhetri, Jahan-
Parwar et al. 2004). Short-term results with a small group of patients who underwent injection with 
CaHA particles showed improved voice quality in one study (Rosen and Thekdi 2004). A work 
with polydimethylsiloxane (PDMS) particles injected into the paraglottic space under 
microlaryngoscopy and general anaesthesia was conducted to study the morbidity and voice quality 
of patients. No complications attributable to PDMS particles occurred. Voice quality was 
comparable to other methods in a 4 month follow-up (Sittel, Echternach et al. 2006).  Polyamide 
acryl hydrogel is widely used as permanent facial tissue filler in plastic surgery.  A preliminary 
study shows that it is suitable also for injection laryngoplasty (Lee, Son et al. 2007). In conclusion, 
initial results with new synthetics are promising, but all of these studies share the same 
shortcomings of limited follow-up and small cohorts. Permanence of augmentation and possible 
foreign-body reactions need yet to be studied.  
 
Xenologous grafts 
Bovine collagen and hyaluronic acid are xenografts with similar theoretical advantages in this 
indication; both are readily available and viscoelastic properties are good. Bovine collagen 
(Zyderm®) was first introduced in the larynx in 1986 with good vocal results initially (Ford and 
Bless 1986). Since its introduction the use of bovine collagen has been controversial due to 
hypersensitivity reactions that have been encountered from 0% to 9.8% of patients ranging from 
local erythema and itching to occasional  systemic reactions such as arthralgia, arthritis, fever, 
urticaria and generalized swelling (Anderson and Sataloff 2004).  Skin testing 4 weeks prior to 
operation was recommended, but negative skin-test did not assure clinical non-reactivity (Courey 
2001). High resorption rate of non-cross-linked collagen also became evident. The bovine collagen 
implant is sensitive to the collagenase secreted by host fibroblasts. To address this, the use of 
glutaraldehyde-cross-linked (GAX) collagen (Zyplast®) was developed. The cross-linking makes 
the implant practically insensitive to collagenase, improving the stability of augmentation, and 
hypersensitivity rate was also reduced to less than 1% (Remacle, Dujardin et al. 1995).  Bovine 
collagen never received FDA approval for intralaryngeal use partly because of concerns about the 
delayed hypersensitivity reactions on the laryngeal airway (Anderson and Sataloff 2004). Another 
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concern with bovine collagen is the development of autoimmune collagen vascular diseases. A 
higher incidence of dermatomyositis and polymyositis in patients exposed to bovine collagen has 
been reported than would be expected in the general population (Anderson and Sataloff 2004). 
Bovine spongiform encephalopathy (mad cow disease), also became an issue of major concern in 
the 1990s. 
 
Hyaluronic acid (HA) is a polysaccharide and a universal component of the extracellular matrix 
with two commercially available products. Hylan-b gel is an extract derived from rooster combs 
and therefore not recommended for patients allergic to avian products.  Restylane is produced by 
microbiologic engineering techniques (Kwon and Buckmire 2004).  Vocal results of Hylan-b gel 
compared well to bovine cross-linked collagen in one study (Hertegard, Hallen et al. 2004). 
Restylane-related granulomatous foreign-body reaction has been reported in plastic lip 
augmentation despite of its proposed nonantigenic properties (Fernandez-Acenero, Zamora et al. 
2003). 
 
Homologous grafts (allografts) 
The adverse effects related to collagen particles from foreign species led the biomedical industry to 
search for human form of collagen for injection. Two homologous grafts, Dermalogen® 
(Collagenesis, Beverly, MA) and Cymetra® (LifeCell Corp., Palo Alto, Calif.), have been 
developed.  Dermalogen is not presently available.  Cymetra® is an injectable form of micronized 
Alloderm that is made of cadaveric dermal tissue processed to remove all the cellular components 
thereby reducing the risk of host versus graft reaction. Preliminary short-term follow-up studies 
support the biocompatibility of Alloderm (Pearl, Woo et al. 2002; Karpenko, Dworkin et al. 2003; 
Milstein, Akst et al. 2005). The permanence of augmentation with Alloderm was contradictory in 
two short-term studies (Pearl, Woo et al. 2002; Karpenko, Dworkin et al. 2003). A later study with 
an average of 11 month follow-up suggested that stability of medialization with Alloderm may last 
longer than previously reported (Milstein, Akst et al. 2005).  A report of abscess formation in the 
vocal fold after injection of micronized Alloderm has been published (Zapanta and Bielamowicz 
2004). Further long-term studies are warranted.  Like bovine collagen, Cymetra can be administered 
in several ways through a thin needle: trancutaneously, transorally or through a rigid laryngoscope 
in the operating room. Disadvantages include high price and a theoretical disease transmission risk 
(HIV, hepatitis etc.). 
 
Autologous grafts 
Autograft is optimal in terms of biocompatibility, easy availability and low cost. Efforts with 
autologous cartilage and bone dust in the 1950s were not satisfactory (Dedo, Urrea et al. 1973). 
Hence, autografts were abandoned for decades until autologous fat was tested in an animal model 
(Hill, Meyers et al. 1991; Zaretsky, Shindo et al. 1995). Clinical trials in humans with fat injection 
in UVFP showed promising vocal results (Mikaelian, Lowry et al. 1991; Brandenburg, Kirkham et 
al. 1992).  Fat is easily harvested from the abdominal skin, has feasible viscoelastic properties, is 
easily injected, and well tolerated by the vocal fold. The main disadvantage of fat is an 
unpredictable absorption after three months, which suggested fat as the ideal method for temporary 
vocal fold medialization in patients in whom return of vocal fold motion is expected (Shindo, 
Zaretsky et al. 1996).  Although the rate of resorption expresses high variability between 
individuals, in many cases repeat injection procedures are necessary to maintain adequate vocal fold 
bulk (Kwon and Buckmire 2004).  Efforts to enhance fat graft survival have been reported in animal 
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studies. A study with rabbits compared graft volume survival at 6 months using standard fat 
injection and injection of preadipocytes into the vocal fold.  Preadipocytes are precursor cells that 
are capable of replication and differentiation into mature adipocytes.  Injecting  preadipocytes did 
not enhance graft survival.  In rabbits, graft volumes obtained with standard fat injection were 
superior to the ones obtained by preadipocyte injection (Glatz, Kalkanis et al. 2003).  The lack of 
stability has promoted opinions that fat is not optimal in the treatment of UVFP (McCulloch, 
Andrews et al. 2002; Laccourreye, Papon et al. 2003).  However, the use of fat in UVFP is still 
widespread, and advocated in a recently published textbook of voice surgery, once specific 
technical details such as patient selection (small glottal gap), non-traumatic harvesting, site of 
injection and 30 % over-correction initially are carefully considered (Sataloff 2005).  
 
Autologous collagen (Autologen®, Collagenesis, Beverly, Massachusettes) was introduced at first 
to treat patients with vocal fold scarring, atrophy, and focal defects (Ford, Staskowski et al. 1995). 
Autologous collagen-fiber injectate was prepared from a graft harvested under local anesthesia from 
the patient´s own abdominal skin and shipped to the biotechnical company for processing, which 
took 3-4 weeks. Autologen could then be stored in refrigerator temperatures for up to six months.  
Injection into the vocal fold in an out-patient setting transorally was performed later through a fine 
27-gauge to 30-gauge needle. Autologous collagen is no longer commercially available (Remacle, 
Lawson et al. 2006). 
 
The origin, composition, and permanency of different injection materials are summarized in Table 1 
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2.4.2. Laryngeal framework surgery 
 
Laryngeal framework surgery is divided mainly into thyroplasty type I and arytenoid 
adduction/rotation. Both techniques were conceptualized and described in two landmark articles by 
the same author (Isshiki, Morita et al. 1974; Isshiki, Tanabe et al. 1978).  However, the first 
description of laryngeal framework surgery dates back a century (Payr 1915).  A number of 
subsequent authors described variations including a Finnish pioneer of otolaryngology (Meurman 
1952).  Meurman named his technique mediofixation of the vocal cord.  He transplanted a piece of 
costal cartilage, which was inserted subperichondrially between the thyroid cartilage ala and the 
internal laryngeal muscles of the paralyzed side through an anterior laryngofissure under local 
anesthesia. Laryngeal framework surgery was popularized in the United States by Koufman, who 
also introduced the term medialization laryngoplasty to describe all types of surgical manipulations 
to medialize the vocal fold (Koufman 1986).  
 
Thyroplasty type I with or without arytenoid adduction is currently considered as the gold standard 
against which all other methods of surgical treatment of UVFP are judged (Bielamowicz 2004; 
Kwon and Buckmire 2004).  Thyroplasty type I essentially involves medialization of the vocal fold 
by its inward displacement with an implant placed through a window in the thyroid cartilage 
lamina. The procedure is performed under local anesthesia from an incision on the neck using the 
patients´s vocal feedback to determine the ideal size of the implant. Nasofiberoptic visual control 
can also be useful. This adjustability together with reversibility are quoted to be the greatest 
advantages of thyroplasty type I (Koufman 1986). Various modifications of the operative technique 
(Netterville, Stone et al. 1993; Montgomery and Montgomery 1997) and the implant material have 
been introduced over the years. Silicone (Koufman 1986), hydroxylapatite (Cummings, Purcell et 
al. 1993), expanded polytetrafluoroethylene or Gore-Tex® (McCulloch and Hoffman 1998) and 
titanium (Friedrich 1999) have all been reported as prosthesis materials with minor morbidity. 
Resorption is not a problem with artificial implants, and vocal results are long-lasting in the 
treatment of glottal insufficiency (Lu, Casiano et al. 1996; Lundy, Casiano et al. 2000; McCulloch, 
Hoffman et al. 2000; Laccourreye, El Sharkawy et al. 2005; Dursun, Boynukalin et al. 2008). 
Disadvantages of this method include the demand for advanced technical skill of the surgeon, 
postoperative oedema and haematoma with a possible airway compromise, wound infection, 
mucosal perforation and dislodgement or extrusion of the implant (Harries 1996). Many surgeons 
prefer to use steroids and antibiotics routinely to avoid immediate postoperative complications 
(Sataloff 2005). 
 
The main methodical drawbacks of thyroplasty type I are inability to correct a wide posterior glottal 
gap and a difference in the horizontal plane of the two vocal folds. These can be best addressed with 
arytenoid adduction, which is also performed under local anesthesia through a skin incision at the 
level of the larynx (Isshiki, Tanabe et al. 1978). Two nylon sutures are placed in the muscle process 
of the arytenoid cartilage. The sutures are then passed through the thyroid lamina and tied on it.  
The sutures pull the muscle process anteriorly rotating the arytenoid to the adducted position 
thereby closing the gap between the vocal folds posteriorily.  As the vocal fold is adducted, the 
vocal process of the arytenoid simultaneously moves downward correcting the horizontal plane as 
well (Isshiki, Tanabe et al. 1978). The voice can be fine-tuned by adjusting the tightness and 
direction of the sutures based on vocal feedback.  Since atrophy of the TA muscle usually results 
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from recurrent nerve paralysis, thyroplasty type I or IL is added to arytenoid adduction to restore 
the volume of the vocal fold for optimal vocal performance (McCulloch, Hoffman et al. 2000).  
Cricothyroid subluxation and adduction arytenopexy (Zeitels 2000) are alternative techniques with 
a similar goal as arytenoid adduction. 
 
2.4.3. Laryngeal reinnervation  
 
The ideal goal of treatment should be the return of normal function.  None of the previously 
described surgical techniques restore that. In theory, reinnervation of the paralyzed vocal fold 
would mend all malfunctions simultaneously with return of movement, mass, and tone.  Laryngeal 
reinnervation, however, has proved to be difficult.  The main purpose of a reinnervation procedure 
is to prevent denervation atrophy of laryngeal muscles.  Return of movement is not achieved.  
Several reinnervation procedures for the paralyzed vocal fold have been described using 
anastomosis of the recurrent nerve to the ansa cervicalis, phrenic nerve, preganglionic symphatetic 
neurons, hypoglossal nerve, and nerve-muscle pedicles (Rubin and Sataloff 2007). 
 
Attempting a direct nerve anastomosis of the RLN often leads to laryngeal synkinesis (Crumley 
1985).  Reinnervation using the anastomosis of the ansa cervicalis to the recurrent nerve provides 
weak tonic innervation to the intrinsic laryngeal muscles without return of movement.  It is reported 
to improve vocal quality and restoration of the mucosal wave (Crumley 1991).  Nerve-muscle 
pedicle technique involves implanting a piece of strap muscle innervated by the ansa cervicalis into 
one of the denervated laryngeal muscles, usually the LCA or TA (Tucker and Rusnov 1981; Tucker 
1989).  The results of the nerve-muscle pedicle technique can be further improved by combining 
medialization to reinnervation (Tucker 1999).  Selective reinnervation of the abductor and adductor 
muscles of the larynx has been introduced with the intent of restoring bidirectional motion of the 
vocal folds in bilateral vocal fold paralysis.  The combination of phrenic reinnervation of the PCA 
(abductor) and ansa cervicalis reinnervation of the adductor group has been reported in an animal 
model (Crumley 1984; Marie, Dehesdin et al. 1989).  Although not yet published, an impressive 
result of selective reinnervation in humans was presented at a voice surgery congress in Paris 3 
April 2009 by Dr. Marie and his colleagues from Rouen, France.  In a female patient with bilateral 
vocal fold paralysis after thyreoidectomy, the return of abduction and normal breathing without 
compromising voice had been achieved with this new technique.  Another new promising technique 
of motion-specific laryngeal reinnervation has been demonstrated with cats by muscle-nerve-muscle 
neurotization. The paralyzed TA muscle is reinnervated by way of axons that sprout from the 
contralateral innervated TA muscle through an interposed nerve graft thus avoiding laryngeal 
synkinesis (Hogikyan, Johns et al. 2001).  
 
2.4.4. Future perspectives 
 
As the time span of this dissertation expands over a period of ten years, many new perspectives on 
surgery of UVFP have emerged.  The “static” medialization procedures to restore the laryngeal 
function after UVFP have been challenged by efforts to develop a “dynamic” means.  Selective 
reinnervation alone has not been universally accepted.  Already two decades ago, high expectations 
were projected towards the rehabilitation of laryngeal nerve palsy by an implantable pacemaker for 
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direct recurrent nerve or intrinsic laryngeal muscle stimulation (Broniatowski, Tucker et al. 1990).  
Electrical pacing of the PCA muscle in humans has been reported in an effort to restore glottal 
opening in bilateral recurrent nerve paralysis (Billante, Zealear et al. 2002).  An animal study 
evaluated the suitability of a deep brain stimulation electrode for laryngeal pacing (Katada, Van 
Himbergen et al. 2008). The conclusion was that this electrode could reanimate the PCA muscle to 
a normal level in a case of synkinetic reinnervation and to 60 % of the normal level in a case of 
complete denervation. 
 
In the future, advances in vocal fold regeneration through tissue engineering may produce results 
that are applicable to everyday laryngological practice.  Instead of simply replacing vocal fold 
tissues with implants and grafts of uncertain fate, the revised aim is to predictably regenerate 
normal tissue (Ford 2008). The rheological properties of extracellular matrix (ECM) are critical to 
vocal fold oscillation. The acellular components of ECM, proteoglycans and glycoproteins play a 
major role in ECM viscosity and hydration.  Hyaluronic acid (HA), a glycoprotein, has a key role in 
preventing scarring and maintaining the viscoelastic properties of the vocal fold.  Researchers now 
strive to develop a synthetic ECM uniquely suitable to the biomechanical strains of vocal folds 
(Thibeault and Duflo 2008).  The capacity of hepatocyte growth factor to induce deposition of HA 
and reduce scarring in the vocal folds has been demonstrated (Hirano, Bless et al. 2004).  
 
Another application of molecular biology, gene therapy, may be a useful adjunct to enhance nerve 
regeneration in the setting of trauma or neurodegenerative disease. Taking advantage of retrograde 
axonal transport, it is now possible to deliver genes encoding therapeutic growth factors to the CNS.  
Remote injection of viral vectors into the recurrent nerve to deliver neurotrophic factors to the 
nerve´s cell bodies within the nucleus ambiguus has been reported with rats (Heavner, Rubin et al. 
2007).  The aim is to promote nerve regeneration and enhance both nuclear and nerve survival.  
Another form of gene therapy, injection of human insulinlike growth factor 1 gene into the 
paralyzed thyroarytenoid muscle of rat has been documented (Shiotani, O'Malley et al. 1999).  It is 
hoped to prevent or reverse muscle atrophy, and enhance nerve sprouting and muscle reinnervation 
thereby augmenting surgical treatment modalities. 
 
 
2.5. Outcome evaluation of voice surgery 
 
Assessment of voice pathology needs to be multidimensional.  Objective measurements have been 
used in numerous clinical settings to compare pre treatment to post treatment phonatory 
characteristics after a specific surgical intervention.  A basic protocol for assessing voice treatment 
effect has been proposed by The European Laryngological Society (DeJonckere, Crevier-Buchman 
et al. 2003).  It comprises five dimensions: videostroboscopy, perceptual evaluation, acoustic 
analysis, aerodynamic measurement and subjective patient rating of voice quality.  
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2.5.1. Videostroboscopy 
 
Videostroboscopy is a clinical technique for recording and observing vocal fold vibration. The basic 
idea of stroboscopy was first invented as early as 1878.  It was gradually introduced into clinical 
practice in Japan and Europe.  At present, videostroboscopy  is considered  routine in the 
laryngologic examination globally (Bless, Hirano et al. 1987).  The videostroboscopy apparatus 
consists of a stroboscopic (pulsed light) cold-light source, a videomonitor, a recording microphone 
and a videotape-recorder or computer software to store a record of the examination.  An office-
based endoscopy with either a rigid 70° or 90° angled laryngoscope transorally, or a flexible 
fiberoptic nasolaryngoscope in individuals with a hypersensitive gag reflex is performed.  
Laryngeal functions may be observed and recorded during prolonged phonation under standard 
white light or stroboscopic light with image magnification.  Stroboscopy creates an illusion of slow 
motion by generating light flashes either at the same frequency as phonation observed as a still 
image, or a slight variation of the fundamental frequency of phonation seen as movement in slow 
motion.  Asynchronization transforms the duration of a typical laryngeal cycle from 5 milliseconds 
up to between 0.25 and 1 second. The “cycle” therefore represents a montage of many laryngeal 
cycles, rather than documentation of a single cycle as in high-speed photography (Sercarz, Berke et 
al. 1992). The brain is then able to fuse these images of cycles into a perception of motion, since the 
retina only responds to images at a rate of five per second.  Perceptual judgements of the vibratory 
patterns of the vocal folds are based on the knowledge of the cover-body theory and how the 
travelling mucosal wave varies as a function of frequency and intensity (Hirano and Kakita 1985).  
The mucosal wave is analyzed for its symmetry, regularity (periodicity), glottal closure, amplitude 
of vibration (lateral excursion of the fold during vibration) and stiffness (presence of immobility) 
(Bless, Hirano et al. 1987). 
 
Stroboscopy is considered useful in the assessment of UVFP, but the clinicians have to be aware of 
the inherent limitations related to the technique (Sataloff, Spiegel et al. 1991).  Stroboscopy is 
useful because of its sensitivity in demonstrating even a slight gap between the vocal folds and an 
asymmetry of the travelling wave.  The mucosal wave on the paralyzed side appears later, travels 
slower and has diminished amplitude.  This asymmetry is caused by lack of muscle tone, and is 
present in all types of laryngeal paralysis (VN, RLN and SLN).  The resulting aperiodicity of vocal 
fold vibration is easily identified even by inexperienced observers (Sercarz, Berke et al. 1992).  On 
the other hand, severe aperiodicity of vibration in patients with a wide glottal gap impairs the ability 
of the stroboscope to synchronize the light flash.  Adequate signal for analysis is therefore not 
always achieved, especially in aphonic voices that most often warrant surgery (Harries and 
Morrison 1996).  However, state-of-the-art evaluation of UVFP is considered to include 
videostroboscopy (Benninger, Crumley et al. 1994; Rubin and Sataloff 2007). 
 
High-speed photography and high-speed digital imaging have been developed to overcome the 
limitations of stroboscopy with aperiodic phonatory disorders (Kaszuba and Garrett 2007). These 
techniques provide real-time images of successive glottal cycles of the larynx during phonation. 
High-speed photography (pictures taken at a rate of 3000-4000 frames per second) requires 
expensive equipment and technical expertise for proper operation.  The view of the larynx during 
the camera recording is achieved by using a laryngeal mirror which can be technically challenging 
with some patients.  High-speed digital imaging uses standard rigid endoscopes at a sampling rate 
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of 1000 to 8000 frames per second. The recorded events with both techniques are then played back 
and analyzed in ultraslow motion.  Technical difficulty, combined with high cost and time 
expenditure necessary to complete the examination, have limited the clinical use of these methods.  
  
2.5.2. Perceptual evaluation 
 
No simple association exists between voice production, subjective auditory perception, and 
objective acoustic data.  When assessing patients after a surgical procedure it is an advantage to 
have preoperative values as a reference to postoperative measurements.  Perceptual evaluation of 
voice is often carried out by a panel of voice professionals who listen to recorded voice samples of 
connected speech.  Despite of the difficulties in standardizing the task, it is still valued by many 
clinicians, since the ultimate goal of surgery is voice that sounds clear and healthy (Kreiman, 
Gerratt et al. 1993).  The Japanese GRBAS system is probably the most widely used scale due to its 
relative simplicity (Behrman 2004).  It consists of five dimensions of voice quality (Grade, 
Roughness, Breathiness, Asthenia, Strain) with a score of 0 to 3 assigned in each domain (0 = 
normal voice; 1 = minor dysfunction; 2 = moderate dysfunction; 3 = severe dysfunction).  Even this 
scale carries the problem of intra- and interrater reliability, the general ‘grade’ value as well as 
‘roughness’ and ‘breathiness’ of voice are evaluated by professionals with moderate reliability and 
interrater consistency (De Bodt, Wuyts et al. 1997).  
 
2.5.3. Acoustic analysis 
 
The voice of dysphonic patients can be analyzed objectively.  The voice sample is recorded in a 
sound-proof booth and consists typically of sustained vowel phonation.  Computer programs like 
Computerized Speech Lab®, CSpeech® and Dr.Speech® are available to provide a 
multidimensional voice analysis.  Acoustic parameters analyzed include measures of perturbation 
(irregularity of frequency and amplitude), fundamental frequency and the relation of noise 
components to harmonic signal.  Acoustic analysis is an attractive method for assessing 
pathological voice because it is easy to obtain, noninvasive, and provides objective data.  However, 
perturbation measures rely on the inherent ability to determine accurate fundamental frequency.  
This may be difficult to obtain with severely dysphonic voices as in UVFP, which are often only 
marginally periodic (Kaszuba and Garrett 2007).  UVFP results in a combination of insufficient 
glottal closure and asymmetry in vocal fold mass.  The perturbation measures of voice acoustics 
reflect these physical facts in two different but interrelated ways.  Irregular glottal pulses are heard 
as roughness of voice and reflected by jitter (Rontal, Rontal et al. 1983),  a cycle-to-cycle frequency 
variation.  Shimmer, a cycle-to-cycle amplitude variation increases with poor and inconsistent 
contact between the vocal fold edges (Yumoto 1983).  In addition to period-to-period variations, 
inconsistent or absent vocal fold closure leads to air leakage through the glottis.  It is acoustically 
characterized by high-frequency noise.  The noise-to-harmonic ratio (NHR) gives an estimation of 
the proportion of aperiodic to periodic signal produced by the vocal folds.  NHR seems to integrate 
both principal components of hoarseness: breathiness and roughness (Yumoto 1983).  The 
reliability of the commercially available acoustical analysis software programs has raised some 
criticism.  Perturbation values in particular agree poorly between programs, which may prevent 
comparison of data from one institution to another (Bielamowicz, Kreiman et al. 1996).  
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2.5.4. Aerodynamic measures 
 
The maximum phonation time (MPT) and the s/z ratio are aerodynamic measures of maximum 
vocal performance that require only a stopwatch for instrumentation. They provide the clinician 
with an easy measure of phonation duration, which correlates to the integrity of phonatory glottal 
closure.  MPT is assessed by asking the patient to take a deep breath and sustain the vowel /a/ for as 
long as possible on a continuous expiration.  The s/z ratio is a statistic of the relative durations of 
maximum phonation of the phonemes /s/ and /z/.  In UVFP, depending on the position of the 
paralyzed vocal fold and the width of the gap during phonation, MTP may vary from a few seconds 
to 20 seconds.  Normative mean values for adults are 26 seconds for men and 21 seconds for 
women (Colton and Casper 1996).  The validity and stability of this measure on repeat trials has 
been questioned, since age, sex, size, general health condition, cooperation and instructions have an 
influence on the results (Behrman 2004).  However, MPT is feasible, when follow-up data from the 
same patient are to be analyzed (Hirano 1989). 
 
2.5.5. Other physiologic measures 
 
Several laboratory techniques used in experimental clinical voice research are also available.  
Electroglottography, photoglottography, ultrasound glottography, and videokymography all monitor 
the vibratory pattern of the vocal folds (Kaszuba and Garrett 2007).  They are considerably less 
common, however, and require specialized instrumentation that is frequently unavailable in routine 
clinical practice (Behrman 2004). 
 
2.5.6. Subjective evaluation of voice quality 
 
Patient self-rating scales are used in laryngology to quantify the psychosocial consequences of  
voice disorders.  While perceptual judgements by educated observers and objective measurement 
can produce valuable data, they do not provide insight into why patients with similar voice 
disorders experience differing levels of handicap and disability.  The Voice Handicap Index (VHI) 
was developed as a psychometrically validated tool to demonstrate treatment effectiveness by 
relating clinical and more objective results to the patients´ subjective experience (Jacobson, Johnson 
et al. 1997).  It consists of 30 statements that reflect the variety of experiences encountered by the 
patient with a voice disorder. The statements are divided into three subscales each consisting of 10 
questions; Functional, Emotional and Physical.  Patients report the frequency of each experience on 
a five-point equally-appearing scale (never, almost never, sometimes, almost always, always).  The 
impact of dysphonia on the quality of life has been reported to be substantial even when compared 
with other chronic diseases such as angina pectoris, sciatica, chronic sinusitis and back pain 
(Benninger, Ahuja et al. 1998).  Especially patients with vocal fold paralysis express problems 
related to the ability to cope with work and other daily tasks.  It is interpreted to be due to the 
impact of incomplete glottic closure (stabilization of the intrathoracic pressure) on lifting and 
straining and other daily activities (Benninger, Ahuja et al. 1998).  Other widely used dysphonia-
specific quality-of-life instruments include Voice-Related Quality of Life (VQROOL) (Hogikyan 
and Sethuraman 1999) and Voice Outcome Survey (Gliklich, Glovsky et al. 1999). 
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3 Aims of the study 
 
The aim of this work was to study how the autologous fascia complies in the vocal fold as an 
injected filler.  Injection laryngoplasty with autologous fascia (ILAF) was performed on humans 
and animals with UVFP. The effects of extreme processing of fascia (mincing) on the stability of 
augmentation and on the host versus graft tissue reactions were of special interest. 
 
Specific aims were as follows: 
1. To analyze fascia graft survival and tissue reactions histologically in an animal model. (I) 
2. To report initial results in humans after ILAF. (II) 
3. To report the intermediate term (5-32 months) results after ILAF. (III) 
4. To analyze glottal closure and vibratory characteristics of the vocal folds by videostroboscopy 
after ILAF (IV) 
5. To present long-term (3-10 years) results after ILAF. (V) 
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4 Patients and methods 
 
The studies are identified with Roman numerals.  All patients in studies II, III, IV and V were 
examined at the Helsinki University Central Hospital, Helsinki, Finland, which is a tertiary referral 
center.  The animal study (I) was conducted at the National Laboratory Animal Center, Kuopio 
University, Finland. 
 
4.1. Surgical technique 
 
 Harvesting and preparation of the free fascia graft for injection laryngoplasty was introduced in 
1998 (Rihkanen 1998).  The fascia lata is exposed through a 2-4 cm longitudinal skin incision on 
the lateral aspect of the thigh under local anesthesia.  A 3 x 2 cm area of fascia is excised with some 
small pieces of subcutaneous fat.  No attempt is made to close the remaining edges of the fascia, 
because it is known to heal eventually with fibrous connective tissue.  Fascia lata is a general donor 
site for free fascia transplantation; no significant muscle prolapse is usually evident (Boyce, Nuss et 
al. 1994).  The fascia is then cut into small pieces to enable injection.  Initially this was done by a 
scalpel on a polyamide-plastic disc. At present, mincing is done with scissors.  The paste thus 
formed (approximately 0.3-0.5 mL) is placed in a 1 mL syringe in retrograde fashion (piston 
removed).  This is best achieved with the help of a septum elevator or by loading the paste first into 
a 2 mL syringe, and then injecting it into the 1 mL syringe.  The 1 mL plastic syringe needs to be 
manufactured for use with the Brunings syringe holder (Karl Storz, Tuttlingen, Germany; 27220) 
for proper fit.  The paste is followed by 0.3 mL of fat to act as a vehicle for emptying the long 
needle (Karl Storz, Tuttlingen, Germany; length 18 cm, O.D. 1.3 mm/ 17.5G; 27200SM).  Rigid 
suspension laryncomicroscopy under general anesthesia with jet-ventilation is performed.  The 
injection is carried out by a Brunings syringe holder.  The first injection site is lateral to the vocal 
process of the arytenoid cartilage and another is directed further anterior on the lateral aspect of the 
fold.  Augmentation of the anterior third of the vocal fold has to be avoided.  Slight over-correction 
is attempted initially.  The injection is aimed deep into the TA muscle (a depth of 2-3 mm).  The 
details of needle position are drawn in figure 1.  After the injection, the vocal fold is stroked with a 
suction tube to smoothen the medial edge.  Patients are discharged from the hospital on the same 
day or on the first postoperative day.  They attend routine control visits 1 and 6 months 
postoperatively.  A supplementary control was scheduled for the clinical trials. The main steps of 
the procedure are illustrated in figures 2 to 6. 
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Fig.1.  Site of injection, superior and coronal view.  Contour of the vocal fold medial edge before the injection 
is marked with a dotted line (®Mari Markkanen-Leppänen 2009). 
 
 
 
 
Fig. 2.  Incision on the lateral aspect of the right thigh. Exposure of the fascia lata. 
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Fig. 3.  Excised fascia, size approximately 3 x 2 cm. 
 
 
Fig. 4. Mincing the graft with scissors. 
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Fig. 5.  Loading the minced fascia with forceps into the 1 mL syringe. An alternate technique is to inject the 
paste with a 2 mL syringe. 
 
 
Fig. 6.  Brunings syringe holder ready for injection. 
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4.2. Animal study (I) 
 
Nine beagle dogs were operated on.  The recurrent nerve was sectioned unilaterally.  Graft 
harvesting and processing, and fascia injection of the paralyzed vocal fold were performed in a 
similar manner to humans.  Two dogs were sacrificed three days after the procedure, one after ten 
days, three dogs at six and three dogs at twelve months.  The larynges were removed and fixed in 
formalin.  Serial coronal paraffin sections of the grafted vocal fold were made. Two contralateral 
mobile vocal folds were used as controls.  Histology of the graft was analyzed by a pathologist. 
 
4.3. Initial clinical trial with patients (II) 
 
During a period of three years (1994-1997) a total of 23 patients underwent ILAF for UVFP. All 
patients had received at least ten sessions of voice therapy before surgery was suggested.  The 
indications for surgery were poor voice quality and inadequate loudness as judged by the patient 
and the phoniatrician, combined with an open glottal gap during phonation on videostroboscopy.  
Five patients were excluded (death of ongoing primary disease before the trial was conducted, a 
child, a senile elderly man, a patient with multiple cranial nerve lesions, a patient with previously 
performed thyroplasty type I).  Finally, 18 patients were included: 9 males and 9 females, mean age 
57 years (range 43-73 years).  Etiology of paralysis was surgical trauma in 12 patients.  Other 
etiologies consisted of tumours (N=3), idiopathic causes (N=2), and one laryngeal trauma. The 
mean duration of paralysis was 2.2 years.  The mean follow-up was 9 months (range 4-25 months).  
Acoustic analysis and MPT were measured to assess the outcome.  Pre- and postoperative data were 
obtained by a sustained vowel phonation recorded in a sound-proof booth.  Jitter, shimmer and 
NHR were calculated with a commercially available computer program. 
 
4.4. Intermediate term clinical trial (III and IV) 
 
The cohort of 23 patients for this study is partly the same as in study I.  For this trial, a 
supplementary control with a longer follow-up was scheduled, and a more thorough workup for 
outcome evaluation was implemented.  In order to find out the impact of a single procedure on 
voice or to be able to carry out a blinded perceptual evaluation 9 patients were excluded: age over 
80  (N=1); age under 16 (N=1), a previous thyroplasty type 1 (N=1); lesions of several  cranial 
nerves (N=1); lost to follow-up (N=2); death due to ongoing  disease (N=2) and need for arytenoid 
adduction soon after fascial augmentation (N=1).  Finally, 14 patients were included: 6 males and 8 
females, aged from 42 to 73, mean age of 59.  The etiology of paralysis was surgical trauma 
(N=10), tumour (N=2), trauma (N=1) and an idiopathic cause (N=1).  The mean duration of 
paralysis was 14 months (range 5 -32 months) and the mean length of follow-up 13 months (range 
5-32 months).  The control visits were conducted during the winter 1997-98. 
 
Perceptual evaluation, acoustic analysis, MPT, and videostroboscopy were chosen for outcome 
measurement.  Perceptual evaluation was carried out by a panel of 4 voice professionals who 
listened to the voice samples of connected speech in a blinded fashion.  A visual analogue scale (a 
line from 0 to 10 cm) was employed with three lines for each voice sample representing the 
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following domains: general grade, roughness and breathiness.  The VAS-scale value of 10 marked 
normal voice, and 0 an aphonic voice.  For the acoustic analysis and MPT, a sustained vowel 
phonation was recorded.  Perturbation measurements (jitter, shimmer) and NHR were calculated.   
 
The videostroboscopy was analyzed in two separate ways and sessions.  Firstly, a frame-by-frame 
analysis was carried out by two of the authors.  To exclude the difference in magnification from one 
recording to another the length of the healthy vocal fold during inspiration was measured and a gap-
index was calculated: glottal gap divided by the length of the healthy membraneous vocal fold x 
100.  Videos under halogen light were available from 12/14 patients preoperatively (one recording 
lost, one patient with a hyperactive gag-reflex not permitting video imaging) and 13/14 patients 
postoperatively (one fiberoptic recording was too blurry for the frame-to-frame analysis).  
Secondly, a panel of four phoniatricians analyzed the mucosal wave only from the postoperative 
non-edited tapes run at normal speed.  Postoperative videos with stroboscopic light were of 
adequate quality for the panel analysis in all 14 patients.  
 
4.5. Long term clinical trial (V) 
 
Between 1996 and 2006 a total of 94 consecutive patients had undergone ILAF for UVFP.  Five 
patients were lost to follow-up.  Nineteen had died.  In order to find out the impact of a single 
injection or to be able to carry out a blinded perceptual evaluation, 13 patients were excluded from 
the study for the following reasons: re-injection with fascia (N=7), arytenoid adduction (N=2) or 
additional lipoinjection (N=1).  Three patients had native language other than Finnish.  Fifty-seven 
patients were invited to participate in the study.  Thirteen patients refused or were unable to attend.  
Forty-four patients attended the follow-up visit.  In one female patient the paralysis had recovered 
and she was excluded.  Hence, 43 patients were included.  The median age at surgery was 55 (range 
14 – 72) years.  Nine patients were males and 34 females.  Median duration of paralysis was 1.1 
(range 0.2 – 46.7) years.  Median duration of follow-up was 5.8 (range 3.3 – 10.0) years.  In 30 of 
the 43 patients, the paralysis was caused by surgical trauma.  The rest were attributable to an 
idiopathic cause (N=3), infection (N=3), tumour compression (N=4), intracerebral hemorrhage or 
infarction (N=2), and intubation trauma (N=1).  Preoperative patient evaluation, voice therapy, and 
indications for surgery were equal to our previous clinical trials.  The one supplementary follow-up 
control for each patient in this study was conducted during the winter of 2006-07.  Perceptual 
evaluation with the GRBAS scale was carried out by a panel of 3 speech therapists.  Acoustic 
analysis (jitter, shimmer, and NHR) were calculated with a computer program.  Postoperative 
videostroboscopy was digitally archived.  The videos were later evaluated by two phoniatricians not 
involved in the operative treatment.  The analyzed parameters were glottal closure, phase symmetry, 
and mucosal wave amplitude.  At the postoperative follow-up visit,  the patients returned the VHI-
questionnaire (Jacobson, Johnson et al. 1997) translated into Finnish.  The VHI was not in use when 
injection laryngoplasty with fascia was initiated in 1996.  Thus, only the postoperative score was 
available for analysis. 
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4.6. Statistical methods 
  
In studies II and III a nonparametric test (Wilcoxon signed rank test; SPSS 7.5) was chosen for all 
parameters, because both series consisted of a small number of subjects, and the distribution of 
results of acoustic analysis was wide and scattered unevenly.  The intrarater reliability of the panel 
and the correlations between objective and subjective measurements were assessed by Pearson 
correlation coefficient (SPSS).   In study IV paired t-test and Pearson’s correlation was applied for 
numeral scales, Wilcoxon signed rank and Spearman correlation for ordinal or nominal values 
(SPSS 10.0).  In study V, statistical analyses were performed with the Wilcoxon signed rank test 
and the Mann-Whitney U-test (SAS 9.1). Associations between different voice parameter values 
were measured by Spearman rank-order correlation coefficients.  Multiple linear regression 
analyses (ANOVA) were performed to determine how preoperative values, sex, age at the time of 
injection, and length of follow-up affected the measurable difference between the voice parameters.  
In all trials p-value < .05 was considered statistically significant. 
 
4.7. Ethics 
 
In the clinical trials informed consent was obtained from all individuals, and the human 
experimentation guidelines of Helsinki University Central Hospital were followed.  The study 
protocols were approved by the Ethics Review Board of the Helsinki and Uusimaa University 
Hospital District.  The animal study received the approval from the Animal Ethics Committee of 
Kuopio University, Kuopio, Finland. 
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5 Results 
 
 
5.1. Histomorphology of the fascia graft, animal study (I) 
 
The objective of the study was to measure the degree of inflammatory response to the graft at the 
host site and the presence of a possible foreign-body reaction.  The effect of extreme graft-
processing and mobile host site on graft survival (reabsorption) were of special interest.  Two dogs 
were sacrificed three days after the procedure, one dog after ten days, three dogs after six months, 
and three dogs after twelve months.   
 
The study verified that fascia was well-tolerated by the vocal fold.  Inflammation was moderate in 
two dogs at three and ten days, but a clear acute inflammation in one dog was seen at three days.  
No inflammatory reaction was present at six and 12 months.  In the beginning there was some 
hemorrhage surrounding the grafts, but no extensive edema, areas of necrosis, or granuloma were 
found at any time.  After one year the fascia graft persisted forming a firm tissue mass with viable 
fibrocytes, collagen bundles with parallel orientation, and blood supply with arterioles and venules.  
Quantification of the volumetric loss of the graft proved to be difficult.  The ellipsoid volume 
formula used in fat graft animal studies (Mikus, Koufman et al. 1995) could not be applied because 
of the irregularity of the fascia graft contour.  
 
Histomorphologically the graft consisted of disrupted fascia at first.  Organization in the form of 
capillary ingrowth from the surrounding muscle tissue began at 3 days.  Signs of collagen 
remodelling began to emerge at 10 days and at six months collagen fibers showed elongation and 
parallel orientation.  At 12 months, the graft consisted of hypocellular dense fibrous tissue with 
well-established vascular structures.  Moderate amounts of fibroblasts were seen in all specimens, 
but they were abundant in two dogs. 
 
Giant-cell foreign-body reaction was found around singular, small, crystal-shaped foreign-bodies, 
which originated from the polyamide (nylon) disc on which the graft was minced.  At six and 12 
months, sparsely spaced crystals in the graft were not noted to form a core of collagen formation or 
major tissue reaction.  The finding of polyamide crystals in the graft at 12 months was important.  It 
was an affirmation to the pathologist that the collagen-rich bundle found in the vocal fold of the 
dogs was man-made.  It also led to a modification of the surgical technique; we began to mince the 
fascia with scissors.  
 
Mild scarring of the thyroarytenoid muscle occurred around the graft.  One dog showed more 
extensive scarring at six months.  The subepithelial layer of the vocal fold remained undisturbed in 
all specimens.  Atrophy of the denervated vocalis muscle in the form of fatty degeneration was 
noted at 6 and 12 months.  
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Fig. 7.  The graft in the canine vocal fold at 12 months under polarizing light. H & E staining. 
 
 
Fig. 8. Collagen fibres of the fascia graft at 12 months under polarizing light. The polyamide foreign-bodies 
are visible as white crystals. 
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Fig. 9. Magnified view of the graft showing arterioles and venules in the graft at 12 months. 
 
 
5.2. Voice quality, initial results (II) 
 
The objective was to measure the short-term results of fascia augmentation. The mean follow-up of 
18 patients was 9 months (range 4-25 months).  The mean MPT doubled from 6.2 seconds (range 1-
15 seconds) to 12.7 seconds (range 4-24 seconds).  This change after intervention was significant (p 
< .01 Wilcoxon).  In the acoustic analysis, significant improvements were measured in jitter (p < 
.001, Wilcoxon); shimmer (p < .01, Wilcoxon) and NHR (p < . 01, Wilcoxon).  The average 
fundamental frequency (Fo) showed no constant change.  However, the Fo-variation diminished 
from 15.1 % to 6.1% (p < .01; Wilcoxon) indicating improved stability of voice. 
 
5.3. Voice quality, intermediate term trial (III) 
 
The objective was to measure the change in voice quality after augmentation of the paralyzed vocal 
fold with autologous fascia graft and to document possible donor site and host site morbidity.  
Fourteen patients were included in the study.  The data for evaluation was collected at a 
supplementary control after the operation.  The mean follow-up was 13 months (5-32 months).  No 
perioperative or postoperative complications related to graft harvesting occurred.  No edema or 
hematoma of the vocal fold with a possible airway compromise after the injection were seen.  All 
patients were discharged from the hospital at the same or the following day.  No antibiotics or 
corticosteroids were given.  At the donor site, two prolapses of the vastus lateralis muscle occurred 
later, one of which was surgically corrected.  No complaints were made of an aesthetically 
disturbing scar on the thigh.  
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In perceptual evaluation 10 of the 14 postoperative voices (71%) were rated as normal or near 
normal; the grade value was over 7.5 (VAS from 0 to 10).  The improvement (change after 
intervention) was significant for grade (p < .001, Wilcoxon) and breathiness (p <  . 001, Wilcoxon ).  
Pearson correlation quotients measuring intrarater agreement were high: r = 0.93 to r = 0.99.  The 
aerodynamic improvement measured by MPT was statistically significant (p < .01, Wilcoxon).  
Mean values of MPT improved from 5.8 to 11.4 seconds.  The change in MPT was more than 25 % 
in 9 out of 14 patients.  In one patient the MPT was worse after the operation.  Data for acoustic 
analysis were available from 12 patients.  A significant change was measured for absolute jitter (p < 
.01, Wilcoxon), shimmer % (p < .01, Wilcoxon), and NHR (p < .01, Wilcoxon).  The parameters of 
acoustic analysis and perceptual evaluation were not correlated statistically significantly. 
 
5.4. Videostroboscopy, intermediate term trial (IV) 
 
The objective was to assess glottal closure and vocal fold vibration by videostroboscopy after ILAF 
in UVFP.  Possible stiffness, scarring, or other possibly harmful consequences of the graft on the 
viscoelastic properties of the vocal fold were of special interest.  Also, a visual estimate of the 
persistence of fascia augmentation, and the ability of the graft to close the glottal gap were 
addressed.  Correlation between mucosal wave findings and other voice quality parameters was 
analyzed.  The patients in this work were the same as in the intermediate term study (III). There is a 
discrepancy in the original article between the text and Table 2 (videostroboscopy analyzed frame-
by-frame); the number of patients in Table 2 is incorrect.  The number of patients in each category 
of videostroboscopic evaluation has been corrected for this presentation. 
 
No signs of chronic inflammation with granuloma formation or scarring were evident at the follow-
up.  The paralyzed vocal fold was bowed in 11 patients before the operation.  A slight bowing was 
still seen in 5 patients after the procedure suggesting either inadequate augmentation initially, or 
slight reabsorption of the graft during the follow-up.  No over-corrected protrusion of the vocal fold 
was seen postoperatively in any patient, the graft had been molded to appropriate size by the 
dynamic forces exerted on the vocal fold.  The relatively small volume of fascia (< 0.5 mL) used in 
this series seems to be sufficient for augmentation in most patients. 
 
The frame-by-frame analysis was carried out in patients in whom a successfully recorded 
preoperative (N=12) and postoperative (N=13) video was available. Analysis of the preoperative 
videos under cold light revealed a large glottal gap with no contact between vocal folds during 
phonation in 10 subjects.  Two subjects had a partial contact of the anterior parts of vocal folds 
under stroboscopic light.  Preoperative stroboscopy failed in 11 patients because the voices were too 
aperiodic to trigger the stroboscope demonstrating irregular or absent vocal fold vibration.  Only 
one patient had a symmetric mucosal wave in phase and amplitude. 
 
Postoperatively 11 patients had complete or partial glottal closure, and two patients had an open 
glottal gap.  The mean gap-index (the gap width in relation to the vocal fold length) was 
preoperatively 7.21 and postoperatively 1.65.  The change was significant (p < .001, paired t-test).  
Postoperatively vocal fold vibration with phase synchrony was present in 8/13 patients (66%).  One 
postoperative fiberoptic stroboscopy was too blurry for the frame-by frame analysis, but of adequate 
quality for the panel evaluation. 
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In the postoperative videostroboscopy (N=14) run at normal speed the panel of phoniatricians 
agreed that 13 patients had complete or partial glottic closure and one patient had an open glottal 
gap during phonation.  The mucosal wave demonstrated phase synchrony in 11 patients (78%).  The 
panel ratings were in accordance with the frame-by-frame analysis of the authors.  
 
When the perceptual evaluation and the postoperative videostroboscopy by the panel were 
compared, a high correlation was noted between vocal fold phase synchrony and breathiness 
(Spearman 0.679, p < .01).  Statistically significant correlation was found also between phase 
synchrony and jitter, shimmer and NHR of acoustic analysis (Spearman 0.648, p < .05; Spearman 
0.648, p < .05; Spearman 0.650, p < .05, respectively).  The measured maximum postoperative gap 
between the vocal folds (gap-index) correlated statistically significantly not only to the perceived 
voice quality (grade: Spearman 0.665, p < .01; breathiness: Spearman 0.741, p < .01), but also to 
the acoustic parameters (jitter: Spearman 0.779, p < .05; shimmer: Spearman 0.629, p < .05; NHR: 
Spearman 0.680, p < .05). 
 
5.5. Voice quality and videostroboscopy, long term trial (V) 
The objective was to measure the stability of outcome after a single injection of fascia.  Only 
patients with fascia injection as the first and only phonosurgical procedure were included.  Forty-
three patients attended only one follow-up visit in this retrospective trial. Median duration of 
follow-up was 5.8 years with a wide range (3.3 – 10.0). 
 
In perceptual evaluation, the improvement after intervention was statistically significant (p < .01, 
Wilcoxon) in all domains of the GRBAS-scale except strain.  In acoustic analysis the average 
proportion of jitter was reduced significantly from 5.25% to 2.61% (p < .01, Wilcoxon).  The 
change in average shimmer and NHR was not statistically significant. Postoperative 
videostroboscopy showed complete or partial glottal closure in 83% of patients. Mucosal wave 
symmetry was detected in every cycle or most cycles in 74% of patients, and mucosal wave 
amplitude symmetry was present in 58% of patients.  Postoperative mean VHI-score was 35 
(median 29).  VHI was below 30 in 24 of the 43 patients (56%), while 9 (21%) considered their 
voice to be poor (VHI over 60).  The scale of VHI ranges from 0 to120.  
 
Multiple regression analysis with single acoustic and perceptual parameters and VHI-scores showed 
that the length of follow-up and delay from onset of paralysis to injection laryngoplasty had no 
significant effect on the results.  The results were neither dependent on the patient´s age.  In 
perceptual evaluation, severely disturbed preoperative voice (high grade value) correlated with poor 
outcome (Spearman 0.404, p < .05).   The results of patients whose paralysis was caused by chest 
surgery (N = 7) were clearly below the average.   
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6 Discussion 
 
The need for safe and stable soft-tissue filler in reconstructive and aesthetic surgery is widely 
acknowledged.  No single material to date has fulfilled all of the ideal requirements.  Based on the 
results of this work, a new application for autologous free fascia transplantation has been 
established.  Fascia seems applicable for long-term treatment of UVFP with certain limitations.  
 
 Injection of fascia deep into the vocal fold is not followed by haematoma or extensive oedema 
compromising the airway.  According to the experiment with canine vocal folds, the fascia graft 
attracts only moderate inflammatory response at the host site without areas of necrosis, thus 
avoiding the need for antibiotics and corticosteroids postoperatively.  The graft induces no chronic 
inflammation or formation of granulation tissue.  Only mild scarring occurs around the graft.  As 
the result, the vibratory medial margin of the vocal fold remains intact.  This allows the return of a 
normal vocal fold mucosal travelling wave, once sufficient augmentation and adequate glottal 
closure are achieved.  The viscoelastic properties of the injected minced fascia graft are not equal to 
the superficial lamina propria of the vocal fold mucosa.  Thus, injection laterally and deep into the 
TA muscle is required.  
 
The results of our animal study showed that extreme processing of the graft did not lead to 
increased phagocytic activity.  Nor did the dynamics of the host site lead to deterioration of the 
graft.  Quantification of volumetric loss of the injected graft at one year postoperatively in the 
animal study proved to be difficult because of the irregular stellar contour of the graft. Some 
compaction of the graft was evident, which was interpreted to be the result of collagen remodelling.  
The graft seemed to be integrated into the vocal fold tissue with blood vessels and viable fibrocytes.  
 
The reported presence of polyamide particles in the vocal fold as a result of  mincing the graft  with 
a scalpel on a polymer plate has caused some concern (Kwon and Buckmire 2004).  From our point 
of view, this finding in the animal study was important.  Firstly, the polymer foreign particles 
amongst the graft affirmed the pathologist in our study that the collagen-rich bundle found in the 
vocal folds of the dogs was indeed man-made.  Another animal study with ILAF had just previously 
stated that no graft was found in the histological sections of the vocal folds of six dogs with UVFP 
and a follow-up of 3-12  months (Rodgers, Abdul-Karim et al. 2000).  It is difficult to explain why 
Rodgers was not able to find the graft from any of the specimens.  The operative technique they 
applied was identical to ours.  He states that although their pathologist had to examine the 
specimens in a blinded fashion, the side of the injection was readily identifiable in every specimen 
as there was significant muscle atrophy compared to the non-injected side.  It is possible that the 
main bulk of the graft could have been missed, since only three coronal sections were made from 
each vocal fold.  Secondly, the finding of foreign-bodies in the graft also led to a modification of 
the surgical technique. After conducting another animal study which confirmed the origin of the 
foreign-bodies to be the polymer plate, the authors commenced processing the graft with scissors 
(Rihkanen, Kaliste et al. 2003). 
 
Our results with autologous fascia have been supported by a study which reported the combined 
results of an animal model and a clinical trial using a similar technique of ILAF (Duke, Salmon et 
al. 2001).  Eight dogs underwent unilateral autologous fascia injection augmentation with 
simultaneous contralateral lipoinjection.  The dogs were sacrificed at 12 weeks.  Histological 
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analysis of canine larynges revealed high graft yield variability for both graft materials, mean graft 
yield being 32.7 % (range 4.8 % - 83.9 %) for fascia and 46.6 % (range 6.7 % - 95.7 %) for fat. The 
difference was not significant (p = .57).  Host inflammatory response was graded as mild in all 
animals.  It is noteworthy that the recurrent nerve was not sectioned before injection, and that both 
vocal folds were augmented simultaneously.  Mobile augmented vocal folds during barking and 
coughing could expedite the exit of the graft and explain the modest yield. 
 
In humans, vocal results after ILAF were good in our short term and intermediate term studies.  
Significant improvement was achieved in blinded perceptual evaluation, acoustic analysis and 
MPT.  The return of mucosal wave was witnessed in videostroboscopy after successful injection 
augmentation.  No over-correction with protrusion of the vocal fold was encountered; graft 
removals were therefore not necessary.  This would suggest that the amount of fascia paste injected 
is not very critical, as long as glottal closure is achieved. Although not reported in our articles, 
relatively small volume of fascia (< 0.5 mL) is sufficient for augmentation in most patients.  Fascia 
is virtually cost-free and readily available in large amounts from the thigh under local anaesthesia.  
Only minor complaints of donor site morbidity were met. 
 
Another research group has examined the results of ILAF in humans (Duke, Salmon et al. 2001). In 
the clinical part of the study, 40 patients underwent autologous fascia injection laryngoplasty for 
various etiologies of glottal insufficiency (bowing, UVFP, scarring).  All patients tolerated the 
procedure well.  One cellulitis of the harvest site was encountered and treated with a short course of 
oral antibiotics.  Thirty-eight of the 40 patients reported subjective improvement in their voice after 
the procedure.  Although the graft yield with dogs was low (the results of canine experiment were 
published in the same article), they reported no significant graft resorption problems in patients, 
including some who had postoperative follow-up of two years.  As a result, in contrast to 
lipoinjection, marked overcorrection was not performed when using fascia for injection.  They 
concluded that autologous fascia may give excellent long-term results especially in the older 
patients with mild bowing or small glottal gap.  However, in cases of paralysis, they prefer to 
perform medialization laryngoplasty, usually combined with arytenoid adduction.  
 
Properly prepared, fascia is cited to be a good material for augmentation also in a textbook of voice 
surgery (Sataloff 2005).  The author has tried the technique and variations of it for years.  Major 
problems have been related to mincing.  Obstruction of the injection needle by fascia particles 
resulted once in a breakage of the metal syringe holder.  He reports relatively little resorption to 
take place and advices to avoid excessive over-correction.  According to our experience, mincing 
the graft into tiny pieces, and cleaning the needle by rinsing it with saline immediately after the 
procedure to clear all remnants of fascia from the lumen has to be meticulous.  It is also essential to 
use an injection needle with a 1.1 mm/17.5G lumen (Karl Storz, Tuttlingen, Germany 27200SM). 
 
Another technique taking advantage of fascia grafting has been introduced to treatment of UVFP 
(Nishiyama, Hirose et al. 2006).  It is a modification of a technique that was initially developed to 
treat vocal fold sulcus and scarring (Tsunoda, Takanosawa et al. 1999).  The graft is harvested from 
the temporal fascia.  Under suspension microlaryngoscopy, an incision is made on the lateral aspect 
of the vocal fold and a pocket is undermined under the sulcus or scarred vocal fold mucosa.  A 
single-layer fascia graft is dried and trimmed, and transplanted into the pocket.  In UVFP, the 
incision is made more posteriorly on the vocal fold, and the pocket is created so that the graft is able 
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to rotate the vocal process of the arytenoid medially. The exact placement of the fascia graft is 
unfortunately quite vaguely described in the article.  One-year follow-up of eight patients showed 
improvement of glottal closure measured by MPT and stroboscopy. 
 
Once the safety and acceptable vocal results of injection augmentation of paralytic dysphonia are 
established, the stability of medialization becomes an important issue.  In our long term follow-up 
of median 5.8 years significant improvement of mean jitter and parameters of blinded perceptual 
evaluation were reported.  The mean postoperative VHI was 35.  The length of delay from the onset 
of paralysis to the injection or the length of follow-up after ILAF did not correlate with the result.  
This seems to be in concordance with the findings of our histological study of canine vocal folds 
where the graft was seen to form an integrated, viable mass in the vocal fold at 12 months 
suggesting long term stability with low if any resorption. 
 
As the implants used in thyroplasty type I are synthetic, resorption is not an issue. Therefore, 
laryngeal framework surgery is considered as the gold standard in the treatment of UVFP against 
which the stability of other techniques is measured (Kwon and Buckmire 2004). Oddly though, 
long-term studies of thyroplasty type I or injection laryngoplasty with any material beyond one year 
are few (Behrman 2004).  Most reported trials of thyroplasty type I with various implant materials 
are limited to a 12 month follow-up (Cummings, Purcell et al. 1993; Montgomery and Montgomery 
1997; McCulloch and Hoffman 1998; Friedrich 1999).  One study of 28 UVFP patients compared 
the 1-month results to the 12-month results; the measured parameters attained maximum 
improvement within one month of thyroplasty type I (Lundy, Casiano et al. 2000).  This was 
interpreted to indicate that the result is permanent, if the augmentation is adequate initially.  In 
contrast, some bowing with recurring glottal gap has been reported with thyroplasty type I, if the 
vocal fold volume continues to diminish as a result of muscle atrophy (Tucker 1999; Hogikyan, 
Wodchis et al. 2000).  Such deterioration of results with time was not seen in a recent study, which 
reported the results of 16 UVFP patients treated with thyroplasty type I, and with a follow-up of 1-7 
years (mean 26 months). Outcome data showed excellent results with continued improvements after 
6 months (Dursun, Boynukalin et al. 2008).  
 
Despite of many advantages of the autologous fascia graft, its application into the vocal fold has not 
been popularized during the past ten years.  The need for operating on a remote surgical site for 
graft harvesting may be considered time-consuming and costly in the operating theatre.  The deep 
harvest wound has been considered to add morbidity (Duke, Salmon et al. 2001; Kwon and 
Buckmire 2004).  The technique of ILAF requires general anesthesia with jet ventilation, which 
excludes it from the office.  Elderly patients with circulatory or respiratory comorbidities may not 
endure even a brief general anesthesia. Augmentation with fascia suffers also from the inherent 
shortcomings of injection laryngoplasty.  Large posterior glottal gaps cannot be corrected with 
injection laryngoplasty regardless of material, because sufficient medialization of the arytenoid is 
not achieved, and the vertical disparity between vocal folds cannot be corrected.  
 
The reliability of our results may leave some room for criticism. A basic shortcoming is that a 
randomized controlled protocol was not applied in these series.  The total number of patients 
diagnosed with UVFP at our institution during these studies was not calculated in either clinical 
trial.  No randomization of UVFP patients into groups receiving either no treatment, voice therapy 
alone, or voice therapy followed by surgery was performed.  Randomization of a surgical treatment 
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with a control group receiving no treatment can be considered as ethically questionable.  No 
universally accepted objective pre treatment guidelines suggesting either behavioural or surgical 
treatment in UVFP exist in terms of findings in videostroboscopy or parameters of acoustic 
analysis.  Selection of patients might have been arbitrary and led to selection bias in the clinical 
trials.  However, all patients in our cohorts had received several sessions of voice therapy with 
unsatisfactory outcome before surgery was suggested.  It is thus safe to say that cases with minor 
voice complaints were not included in our series.  
 
In addition, fascia augmentation was performed as the first and only phonosurgical procedure.  
UVFP patients with wide glottal gap and vertical disparity of the vocal processes of the arytenoids 
were not excluded.  In retrospect, our results may have been adversely affected by this.  The result 
of ILAF was especially unsatisfactory when the lesion was caused by an intrathoracic lesion of the 
VN.  It is possible that the distance from the lesion in the thorax to the vocal fold is too great for 
any reinnervation to occur.  Also the surgical trauma in the thorax is apparently severe leading more 
often to a complete transection of the nerve.  This complete denervation results in an extremely 
lateral position of the vocal fold and a wide glottal gap that is difficult to correct with the injection 
technique.  As a result of the present study, the treatment protocol of wide glottal gaps has been 
directed towards laryngeal framework surgery at our institution.  These challenges in the research 
setting of our series are reflected in a review article of evidence-based treatment of paralytic 
dysphonia.  A comprehensive literature survey of outcomes and efficacy  revealed the virtual 
absence of randomized controlled trials addressing this patient population (Behrman 2004).  Only 
one such study design was found, where the injection of bovine collagen was compared with the 
injection of HA (Hertegard, Hallen et al. 2004).  
 
The objectivity and accuracy of outcome measurements is vital to the reliability of results. The 
parameters chosen to measure voice quality in our study agree well with the protocol suggested by 
the European Laryngological Society (DeJonckere, Crevier-Buchman et al. 2003).  An effort 
towards unbiased perceptual and videostroboscopic evaluation was made by using panels of voice 
professionals not involved in the surgical treatment.  In perceptual evaluation, the panels listened to 
the voice samples in a blinded fashion.  To ensure accuracy, all recordings were made digitally.  
Two students of speech sciences with a thorough understanding of voice research recorded the 
voice samples at the supplementary postoperative controls related to these series, and also 
performed the acoustic analysis.   
 
Direct conclusions of the benefits of ILAF over other surgical techniques are impossible to draw.  
We conducted no trial comparing fascia with other injection materials or to thyroplasty type I.  
Although an effort was made to reach all eligible patients, generalization and statistic analysis of the 
data on fascia augmentation are difficult because of small cohorts. The difficulties of conducting a 
retrospective trial with several years of follow-up after a rarely performed surgical procedure were 
encountered also in our series.  Many elderly patients had died of comorbidites (20 %), and several 
patients refused to attend or were lost to follow-up. These facts reduced the number of patients 
originally identified in the computer data base search to half.  Age tends to increase atrophy of the 
vocal fold.  As the median age in clinical trials during the time of injection was 57-58 years, a 
median follow-up of six years is likely to increase the effect of aging to voice quality.   
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Preoperative voice samples of 15 patients were lost during the follow-up in the long-term trial.  The 
number of patients available for each parameter of outcome evaluation varied because of the 
availability of recordings.  The quality of many preoperative recordings (both in videostroboscopy 
and acoustic analysis) was not sufficient for analysis because of the aperiodicity of voice.  This 
seems to be a fact one has to accept when treating and studying extremely hoarse voices.  The 
preoperative voice samples in the long-term study (V) were recorded by several nurses and at two 
different facilities, which provides quite a different setting compared to a prospective study with a 
given number of consecutive patients recorded by the same staff with the same instrumentation.  
The videostroboscopies performed in the 1990s were recorded on a U-matic analogic recorder.  
Comparing those videos with the postoperative digital stroboscopic computerized files could not 
have been carried out in a blinded fashion.  Therefore, only the postoperative videos were used for 
evaluation.  All these reductions in the samples of different parameters have presumably affected 
the power of our cohort to represent the long-term results of fascia augmentation. 
 
The work in vocal fold restoration has progressed through phases of tissue replacement with 
synthetic fillers and biological implants.  The return of normal function remains to be the ultimate 
goal of treatment.  Increasing knowledge of the molecular biology of the vocal fold and nerve 
regeneration probably leads to means of enhancing the recovery of the damaged recurrent nerve and 
the regeneration of atrophied and scarred vocal fold tissue. If the results of the animal experiments 
can be applied to humans, all the complex functions of the larynx could be restored simultaneously.  
Until then, our method appears to offer a practical solution to resolve this complex issue. 
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7 Conclusions 
 
Based on the studies I-V, the following conclusions were drawn:  
 
1. Histological analysis reveals that aggressive processing of fascia does not induce aggravated host 
versus graft tissue reactions.  Fascia is well-tolerated by the vocal fold.  After 12 months, the graft 
was integrated into the host tissue with viable fibrocytes and blood circulation. We were unable to 
measure the exact graft yield because of the irregular contour of the graft.  Some compaction of the 
graft due to collagen remodelling with loss of initial augmentation volume was evident.  Absence of 
phagocytic activity suggests long-term stability of the graft. 
 
2. Significant short and intermediate term improvement of voice quality was achieved in UVFP 
patients after ILAF. 
 
3. ILAF is a safe medialization technique with no immediate surgical complications and minimal 
postoperative morbidity. 
 
4. Fascia induces no chronic inflammation with granuloma formation or stiff scarring of the vocal 
fold.  This enables normal vibration of the vocal fold cover to occur during phonation.  
 
5. The long term results were not as good and not as constant as those at one year.  Wide glottal 
gaps should not be treated with fascia injection.  The results were not dependent on the delay from 
onset of paralysis to surgery or the length of follow-up after ILAF.  Fascia is a stable graft and most 
suitable for cases with less severe glottal insufficiency. 
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